Skip to main content
SpringerLink
Log in

Radioimmunotherapy of Brain Tumors

  • Chapter
  • First Online:
Therapeutic Nuclear Medicine

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 2654 Accesses

Abstract

Despite many technical advances (intraoperative resection control, fluorescence guided resection, advances in external beam radiation techniques) and new consolidated findings on systemic chemotherapy, treatment of malignant gliomas with conventional modalities (surgery, radiation therapy, and chemotherapy) is still highly unfavorable. Total tumor eradication is impossible due to tumor infiltrations into the surrounding normal brain tissue and the limitations given by its limited tolerance. New treatment strategies, therefore, aim for a more selective destruction of tumor cells. Malignant gliomas express several antigens or receptors which are not or only to a minor extent present in normal brain tissue. Administration of radiolabeled monoclonal antibodies targeting these tumor-specific structures, especially when given locoregionally, offers an innovative therapeutic strategy that has demonstrated encouraging antitumor effects and acceptable toxicity in many phase I/II clinical trials. This chapter offers a comprehensive summary of own experiences and results of clinical trials reported in the literature dealing with radioimmunotherapy of malignant glioma and highlights future plans to further develop this therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bartolomei M, Mazzetta C, Handkiewicz-Junak D et al (2004) Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 48:220–228

    CAS  PubMed  Google Scholar 

  • Bigner DD, Brown MT, Friedman AH et al (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16:2202–2212

    CAS  PubMed  Google Scholar 

  • Boiardi A, Bartolomei M, Silvani A et al (2005) Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 72:125–131

    Article  CAS  PubMed  Google Scholar 

  • Brack SS, Silacci M, Birchler M et al (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12:3200–3208

    Article  CAS  PubMed  Google Scholar 

  • Brady LW, Markoe AM, Woo DV et al (1990a) Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme: a pilot study. Front Radiat Ther Oncol 24:151–160 (discussion 161–165)

    CAS  PubMed  Google Scholar 

  • Brady LW, Markoe AM, Woo DV et al (1990b) Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas: a pilot study. J Neurosurg Sci 34:243–249

    CAS  PubMed  Google Scholar 

  • Casaco A, Lopez G, Garcia I et al (2008) Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 7:333–339

    Article  CAS  PubMed  Google Scholar 

  • Cokgor I, Akabani G, Kuan CT et al (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862–3872

    CAS  PubMed  Google Scholar 

  • De Santis R, Albertoni C, Petronzelli F et al (2006) Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res 12:2191–2196

    Article  PubMed  Google Scholar 

  • Emrich JG, Brady LW, Quang TS et al (2002) Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25:541–546

    Article  PubMed  Google Scholar 

  • Goetz C, Rachinger W, Poepperl G et al (2003) Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir Suppl 88:69–75

    CAS  PubMed  Google Scholar 

  • Goetz CM, Rachinger W, Decker M et al (2005) Distribution of labeled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol Immunother 54:337–344

    Article  CAS  PubMed  Google Scholar 

  • Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hauck ML, Zalutsky MR (2005a) Enhanced tumour uptake of radiolabeled antibodies by hyperthermia. Part II: application of the thermal equivalency equation. Int J Hyperthermia 21:13–27

    Article  CAS  PubMed  Google Scholar 

  • Hauck ML, Zalutsky MR (2005b) Enhanced tumour uptake of radiolabeled antibodies by hyperthermia: Part I: timing of injection relative to hyperthermia. Int J Hyperthermia 21:1–11

    Article  CAS  PubMed  Google Scholar 

  • Herold-Mende C, Mueller MM, Bonsanto MM et al (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362–369

    Article  CAS  PubMed  Google Scholar 

  • Hopkins K, Papanastassiou V, Kemshead JT (1996) The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res 141:159–175

    Article  CAS  PubMed  Google Scholar 

  • Kim CH, Bak KH, Kim YS et al (2000) Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 54:235–240

    Article  CAS  PubMed  Google Scholar 

  • Kleihues P, Cavenee WK (2000) Tumors of the nervous system. Pathology and genetics. IARC press, Lyon, France

    Google Scholar 

  • Leins A, Riva P, Lindstedt R et al (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98:2430–2439

    Article  CAS  PubMed  Google Scholar 

  • Lund-Johansen M, Bjerkvig R, Humphrey PA et al (1990) Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50:6039–6044

    CAS  PubMed  Google Scholar 

  • Paganelli G, Grana C, Chinol M et al (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357

    Article  CAS  PubMed  Google Scholar 

  • Paganelli G, Bartolomei M, Ferrari M et al (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–235

    Article  CAS  PubMed  Google Scholar 

  • Paganelli G, Bartolomei M, Grana C et al (2006) Radioimmunotherapy of brain tumor. Neurol Res 28:518–522

    Article  CAS  PubMed  Google Scholar 

  • Patel SJ, Shapiro WR, Laske DW et al (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243–1252 discussion 1252–1253

    Article  PubMed  Google Scholar 

  • Petronzelli F, Pelliccia A, Anastasi AM et al (2005) Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 11:7137s–7145s

    Article  CAS  PubMed  Google Scholar 

  • Quang TS, Brady LW (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972–975

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Zalutsky MR, Bigner DD (2007) Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 7:675–687

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Zalutsky MR, Akabani G et al (2008) A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10(2):182–189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Reist CJ, Bigner DD, Zalutsky MR (1998) Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res 4:2495–2502

    CAS  PubMed  Google Scholar 

  • Riva P, Arista A, Sturiale C et al (1992) Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labeled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51:7–13

    Article  CAS  PubMed  Google Scholar 

  • Riva P, Franceschi G, Frattarelli M et al (1999a) Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res 5:3275s–3280s

    CAS  PubMed  Google Scholar 

  • Riva P, Franceschi G, Frattarelli M et al (1999b) 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma–phase I and II study. Acta Oncol 38:351–359

    Article  CAS  PubMed  Google Scholar 

  • Riva P, Franceschi G, Riva N et al (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601–609

    Article  CAS  PubMed  Google Scholar 

  • Sasaki H, Yoshida K, Ikeda E et al (1998) Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer 82:1921–1931

    Article  CAS  PubMed  Google Scholar 

  • Schold SC Jr, Zalutsky MR, Coleman RE et al (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28:488–496

    Article  PubMed  Google Scholar 

  • Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401

    Article  CAS  PubMed  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  • Todaro L, Christiansen S, Varela M et al (2007) Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 83:135–144

    Article  CAS  PubMed  Google Scholar 

  • Wikstrand CJ, McLendon RE, Friedman AH et al (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130–4140

    CAS  PubMed  Google Scholar 

  • Zalutsky MR (2004) Targeted radiotherapy of brain tumours. Br J Cancer 90:1469–1473

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zalutsky MR (2005) Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med 46(Suppl 1):151S–156S

    PubMed  Google Scholar 

  • Zalutsky MR, Moseley RP, Coakham HB et al (1989) Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807–2813

    CAS  PubMed  Google Scholar 

  • Zalutsky MR, Moseley RP, Benjamin JC et al (1990) Monoclonal antibody and F(ab’)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50:4105–4110

    CAS  PubMed  Google Scholar 

  • Zalutsky MR, Reardon DA, Akabani G et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30–38

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Katharinenhospital—Klinikum Stuttgart, Kriegsbergstr. 60, 70174, Stuttgart, Germany

    Gabriele Pöpperl

Authors
  1. Gabriele Pöpperl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriele Pöpperl .

Editor information

Editors and Affiliations

  1. THERANOSTICS Center for Molecular, Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Bad Berka, Germany

    Richard P. Baum

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pöpperl, G. (2012). Radioimmunotherapy of Brain Tumors. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_730

Download citation

  • DOI: https://doi.org/10.1007/174_2012_730

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-36718-5

  • Online ISBN: 978-3-540-36719-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation